Close this search box.

Bringing psychedelics into the drug development fold

ARTICLE | Product Development

Second-generation psychedelics are being tested in more conventional clinical trials, and starting to yield impressive efficacy

By Selina Koch, Executive Editor 

February 6, 2024 1:59 AM UTC

Psychedelics have gone mainstream. Criminalization and decades of stigma have given way to high expectations for the therapeutic power of psychedelics in an array of mental health contexts.

But even as a large swath of society has done a U-turn in its opinion of psychedelics, investor sentiment has cooled in recent years, as first-generation psychedelic therapies revealed the manifold difficulties of the business model needed to commercialize them.